Recently, Zhejiang Orient Gene Biotech Co., Ltd. took a 51% stake in Shaoxing Jinlu Biotechnology Co., Ltd. through capital increase, which is intended to further promote and improve the layout of the company in molecular diagnostic field. Jinlu Bio has a number of domestic product registration certificates and a stock of more than 100 kinds of reagent products, among which probe preparation is to produce auxiliary diagnostic reagent products for tumor clinical molecular pathology based on repeat-free sequence fluorescence in situ hybridization probe technology. Orient Gene's holding in Shaoxing Jinlu Bio aims to improving the user's experimental experience and boost the promotion of related products in clinical molecular pathology applications nationwide and worldwide by providing a complete set of fluorescence in situ hybridization detection solutions for clinical molecular pathology, from probe reagent products, pre-processing automation equipment to signal interpretation instrument.